Omontys FDA Approval History
FDA Approved: Yes (Discontinued) (First approved March 27, 2012)
Brand name: Omontys
Generic name: peginesatide
Dosage form: Injection
Company: Takeda Pharmaceutical Company Limited
Treatment for: Anemia Due to Chronic Kidney Disease
Marketing Status: Discontinued
Omontys (peginesatide) an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis.
Development timeline for Omontys
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.